Overview

• The company posted a consolidated net loss of Rs 82 crore for Q1 FY2025, improving from a Rs 89 crore loss a year earlier.
• Revenue dipped one percent to Rs 1,934 crore as destocking of a major on-patent product weighed on sales.
• Excluding the destocking impact, the CDMO segment delivered mid-teen revenue growth and stronger EBITDA margins at overseas sites.
• Management expects complex hospital generics to pick up later this fiscal as institutional order cycles align.
• Leadership reiterated its goal to achieve USD 2 billion in revenue with a 25 percent EBITDA margin and high-teen ROCE by FY2030.